Publications scientifiques

2676 PUBLICATIONS

ANNÉE

JOURNAL

PREMIER AUTEUR

TITRE

ANNÉE2026

JOURNALFrontiers in oncology

PREMIER AUTEURIlie SM

TITREAn expression signature of 19 human endogenous retroviruses identifies immunogenic luminal breast cancers likely to respond to immunotherapy.

ANNÉE2026

JOURNALBreast cancer (Tokyo, Japan)

PREMIER AUTEURPopescu BV

TITREBRCA pathogenic variants and response in early TNBC patients treated with neoadjuvant pembrolizumab: outcomes of the BRCAPATH study.

ANNÉE2026

JOURNALAmerican journal of physiology. Cell physiology

PREMIER AUTEURCharlot A

TITREHigh-fat, low-carb diet reduces tumor growth and induces liver metabolism remodeling in a breast cancer mouse model.

ANNÉE2026

JOURNALCell communication and signaling : CCS

PREMIER AUTEURArslan S

TITRESmall extracellular vesicle-mediated transfer of HPV16 transcripts from Ca Ski cells increases proliferation of HPV-negative recipient cancer cells.

ANNÉE2026

JOURNALJournal of gynecology obstetrics and human reproduction

PREMIER AUTEURYacoub N

TITREPrevalence and distribution of high-risk HPV in an organized hospital-based cervical cancer screening cohort.

ANNÉE2026

JOURNALCancer treatment and research communications

PREMIER AUTEURBoudier P

TITREEffectiveness of pegylated liposomal doxorubicin (Caelyx®) monotherapy in patients with metastatic HER2-low breast cancer: a monocentric retrospective study.

ANNÉE2026

JOURNALCancer epidemiology

PREMIER AUTEURDesandes E

TITREAre pediatric central nervous system tumors on the rise in France? A population-based 21-year retrospective study.

ANNÉE2026

JOURNALAnalytical chemistry

PREMIER AUTEUREl Tahech H

TITREBreast Cancer Diagnosis and HER2+ Versus Triple Negative Discrimination by Infrared Spectral Histopathology.

ANNÉE2026

JOURNALBreast cancer research : BCR

PREMIER AUTEURVignot S

TITREPrognostic value of lymphopenia in early breast cancer: learnings from the prospective CANTO cohort.

ANNÉE2026

JOURNALExpert opinion on investigational drugs

PREMIER AUTEURKroemer M

TITREEvaluating the investigational drug landscape for -mutated, estrogen receptor positive, HER2 negative metastatic breast cancer.

Retrouvez aussi

Unités de recherche, établissements

Projets de recherche

Publications scientifiques